Clinical trials: Estrogens
Breast Cancer
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy
With the development of neoadjuvant therapy for tumors, neoadjuvant chemotherapy (NAC) has become one of the most common and effective methods for preoperative systemic treatment of locally advanced breast cancer (LABC).
- Trial name
- NCT04137640
- Testing
- palbociclib combined with letrozole, epirubicin combined with cyclophosphamide and sequential docetaxel
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Shengjing Hospital
Breast Cancer, Cancer
Breast Re-irradiation After Second Ipsilateral Lumpectomy
The purpose of this research study is to test the safety and possible harms of treating breast cancer with reirradiation, after breast surgery.
- Conditions
- Breast Cancer, Cancer, Cancer of the Breast, HER2-negative Breast Cancer
- Trial name
- BRASIL (NCT06867484)
- Testing
- Intensity modulated radiation therapy (IMRT)
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Youssef Zeidan
Hormone Receptor Positive Malignant Neoplasm of Breast
The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population
The main goal of this study is to characterize whether the results of the Oncotype DX® assay affect the physician's treatment recommendations for the adjuvant treatment of women with ER-positive (ER+), early breast cancer (EBC)…
- Trial name
- NCT02347449
- Testing
- Questionnaires, Oncotype Dx Assay
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Breast Cancer
Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT
To examine whether the occurrence of oral mucositis can be reduced by dental oral management in patients by comparing the use of dental oral management through instruction by dental and oral surgeons (dental oral management…
- Trial name
- NCT02376985
- Testing
- Oral management, Everolimus
- Where
- Japan
- Volunteers
- 174 people
- Sponsor
- Comprehensive Support Project for Oncology Research
Metastatic Breast Cancer
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer
This study of hormone positive (estrogen receptor [ER]), metastatic invasive ductal breast cancer looks at functional scanning using positron emission tomography (PET) and patient response to hormone therapy.
- Trial name
- NCT00358098
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AHS Cancer Control Alberta
Metastatic Breast Cancer
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period
PALBO is a Non-Interventional, National Study Of Real-World Evidence In Estrogen Receptor Positive, Her2 Negative Metastatic Breast Cancer Patients Treated With Palbociclib During A 2.5 Years Follow-Up Period.
- Trial name
- PALBO (NCT05135104)
- Testing
- Palbociclib
- Where
- 7 sites in Romania
- Volunteers
- 650 people
- Sponsor
- Asociatia Oncohelp - Centrul de Oncologie Oncohelp
Early Breast Cancer
Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients
This will be a prospective, multicenter, observational study. The primary objective is to record the choice, in clinical practice, of adjuvant hormone therapy (tamoxifen, tamoxifen + LhRh, aromatase inhibitors + LhRh) in…
- Trial name
- GIM 23- POSTER (NCT05730647)
- Testing
- None intervention (observational study)
- Where
- 40 sites in Italy
- Volunteers
- 600 people
- Sponsor
- Consorzio Oncotech
Endometroid Endometrial Cancer
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
This is a 2 stage multi-center study designed to evaluate the efficacy of the combination of alpelisib and fulvestrant in patients with PIK3CA-mutated ER-positive endometrioid endometrial cancers by estimating the objective…
- Trial name
- NCT05154487
- Testing
- Alpelisib Pill, Fulvestrant injection
- Where
- 21 sites in United States
- Volunteers
- 51 people
- Sponsor
- GOG Foundation
Osteoporosis
Study Evaluating Changes In Mammographic Breast Density
The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg…
- Trial name
- NCT00774267
- Testing
- BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 507 people
- Sponsor
- Pfizer
Advanced Metastatic Breast Cancer
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer
This was a national, multi-center, open-label, phase IIIb trial to determine the efficacy and safety of treatment with ribociclib (LEE011) plus letrozole in patients with HR+, HER2-negative advanced (recurrent or metastatic)…
- Trial name
- NCT03096847
- Testing
- ribociclib, letrozole, goserelin
- Where
- 84 sites in Germany
- Volunteers
- 502 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage…
- Trial name
- EMBER-2 (NCT04647487)
- Testing
- LY3484356
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Recurrent Breast Cancer
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
The purpose of this study is to find out what effects this new drug foretinib has on this type of breast cancer, called "triple negative" breast cancer because the cancer tissue is estrogen, progesterone and HER2 receptor…
- Trial name
- IND197 (NCT01147484)
- Testing
- Foretinib
- Where
- 9 sites in Canada
- Volunteers
- 47 people
- Sponsor
- NCIC Clinical Trials Group
Systemic Lupus Erythematosus
Safety of Estrogens in Lupus: Birth Control Pills
Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether women with systemic lupus erythematosus (SLE or lupus) can safely use estrogen.
- Trial name
- NCT00000420
- Testing
- Ortho-Novum 777
- Where
- 15 sites in United States
- Volunteers
- 350 people
- Sponsor
- NYU Langone Health
Prostate Neoplasm
Role of Soy Supplementation in Prostate Cancer Development
This is a randomized study evaluating the effectiveness and direct effect a commercial soy supplement has on prostate cancer and normal prostate tissue.
- Trial name
- NCT00255125
- Testing
- Soy Supplement
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- VA Office of Research and Development
Early Breast Cancer, Metabolic Health
Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy
This clinical trial aims to investigate early metabolic health changes in early breast cancer patients that initiate antihormone therapy.
- Conditions
- Early Breast Cancer, Metabolic Health, Estrogen Receptor Positive Breast Cancer
- Trial name
- EMETA (NCT06623903)
- Where
- Denmark
- Volunteers
- 112 people
- Sponsor
- Aarhus University Hospital
Estrogen Receptor Positive Breast Cancer
A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
This is an open-label, multicentre, 4-arm randomised phase II trial of fulvestrant + AZD2014 versus fulvestrant + everolimus versus fulvestrant alone in patients with ER-positive, HER2-negative advanced or metastatic breast…
- Trial name
- MANTA (NCT02216786)
- Testing
- AZD2014, Everolimus, Fulvestrant
- Where
- 79 sites in France, Georgia and 7 more
- Volunteers
- 333 people
- Sponsor
- Queen Mary University of London
Breast Cancer
A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
This is a Phase 1b, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-c5 administered orally in combination with abemaciclib (VERZENIO®) in…
- Trial name
- NCT04514159
- Testing
- ZN-c5, Abemaciclib
- Where
- 5 sites in United States, Poland
- Volunteers
- 14 people
- Sponsor
- Zeno Alpha Inc.
Obesity, Glucose Homeostasis
Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)
The goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with Bazedoxifene/Conjugated Estrogens (BZA/CE) vs.
- Conditions
- Obesity, Glucose Homeostasis, Postmenopausal Symptoms
- Trial name
- BIM (NCT02237079)
- Testing
- Bazedoxifene/Conjugated Estrogens (BZA/CE)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Tulane University Health Sciences Center
Diabetic Macular Edema
Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema
The drug being tested in this study is low doses of Optina (formerly known as Danazol) (DMI-5207) that may be an effective treatment for diabetic retinopathy and diabetic macular edema (DME).
- Trial name
- NCT02002403
- Testing
- Danazol
- Volunteers
- 34 people
- Sponsor
- Unity Health Toronto
Estrogen Receptor Negative, HER2/Neu Negative
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase II trial studies how well trametinib and v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor GSK2141795 work in treating patients with triple-negative breast cancer (breast cancer cells that do not have…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01964924
- Testing
- Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)